Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinom...Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinoma(G1 EAC)and the recurrence rate after treatment.Methods Sixty patients(aged 20-42 years)with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups(n=30)to receive oral MA treatment at the daily dose of 160 mg(control)or MA plus oral metformin(850 mg,twice a day)for at least 6 months.The treatment could extend to 12 months until a complete response(CR)was achieved,and follow-up hysteroscopy and curettage were performed every 3 months.For all the patients who achieved CR,endometrial expressions of IGFBP-rP1,p-Akt and p-AMPK were detected immunohistochemically.Results A total of 58 patients completed the treatment.After 9 months of treatment,23(76.7%)patients in the combined treatment group and 20(71.4%)in the control group achieved CR;two patients in the control group achieved CR after converting to the combined treatment.The recurrence rate did not differ significantly between the control group and combined treatment group(30.0%vs 22.7%,P>0.05).Ten(35.7%)patients in the control group experienced significant weight gain of 5.7±6.1 kg,while none of the patients receiving the combined treatment exhibited significant body weight changes.Compared with the control group,the patients receiving the combined treatment showed enhanced endometrial expressions of IGFBP-rP1 and p-AMPK with lowered p-Akt expression.Conclusion Metformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC,and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.展开更多
Objective:To observe the clinical effect difference between abdominal acupuncture combined with megestrol acetate and megestrol acetate for advanced cancer-related anorexia.Methods:A total of 60 patients with advanced...Objective:To observe the clinical effect difference between abdominal acupuncture combined with megestrol acetate and megestrol acetate for advanced cancer-related anorexia.Methods:A total of 60 patients with advanced cancer-related anorexia were randomly divided into an abdominal acupuncture combined with oral megestrol acetate treatment group(group A)and oral megestrol acetate treatment group(group B),with 30 cases in each group.Both groups were given nutritional assessment,nutritional supplementation,improvement of constipation,correction of electrolyte disturbance and other general treatments.In addition,group B was given another 160 mg megestrol acetate dispersible tablet once a day.Group A was treated with abdominal acupuncture on the basis of group B treatment,5 times a week,and both the groups were treated for 2 weeks.The appetite visual analog scale(VAS),Karnofsky(KPS)score,and body weight of the two groups were observed before and after treatment,and the clinical efficacy was evaluated.Results:After treatment,the appetite VAS in the both groups were lower than those before treatment,the Karnofsky(KPS)scores were higher than those before treatment,and the differences were statistically significant(both P<0.05).The differences of appetite VAS and KPS score before and after treatment in group A were higher than those of group B,and the differences were statistically significant(both P<0.05).After treatment,the body weights of the two groups were higher than those before treatment,and the difference of group A before and after treatment was higher than that of group B,but the difference was not statistically significant(P>0.05).The effective rate of group A was 76.7%and that of group B was 50%,the difference was statistically significant(P<0.05).Conclusion:Abdominal acupuncture combined with oral megestrol acetate and oral megestrol acetate both can effectively improve the appetite and functional status of patients with advanced cancer-related anorexia.Abdominal acupuncture can improve the curative effect,which is better than that of western medication alone,providing a new idea for the treatment of advanced cancer-related anorexia in the future.展开更多
A rapid and highly selective liquid chromatography-tandem mass spectrometric （LC-MS/MS） method for the determination of megestrol in human plasma was described using medry- sone as internal standard （IS）. Blood sa...A rapid and highly selective liquid chromatography-tandem mass spectrometric （LC-MS/MS） method for the determination of megestrol in human plasma was described using medry- sone as internal standard （IS）. Blood samples were collected from 20 healthy volunteers after oral ad- ministration of 160 mg megestrol acetate dispersible tablets. The analytes were extracted by liq- uid-liquid extraction procedure and separated on a hanbon lichrospher column with the mobile phase of methanol and water containing 0.1% formic acid and 20 mmol/L ammonium acetate （5：1, v/v）. Positive ion electrospray ionization with multiple reaction-monitoring mode （MRM） was employed by monitor- ing the transitions m/z 385.5-325.4 and m/z 387.5-327.4 for megestrol and medrysone, respectively. Under the isocratic separation conditions, the chromatographic rim time was approximately 2.54 min for megestrol and 2.59 min for medrysone. The calibration curve range was from 0.5 to 200.0 ng/mL. The inter-batch and intra-batch precision and accuracy were less than 5.2% relative standard deviation （RSD） and 6.4% relative error （RE）. The proposed method was successfully applied in the bioequivalence study of megestrol acetate dispersible tablets.展开更多
Objective: to study the effect and value of megestrol in the clinical treatment of chemotherapy-induced vomiting of colorectal cancer.Methods: this study was conducted retrospectively. 64 patients with colorectal canc...Objective: to study the effect and value of megestrol in the clinical treatment of chemotherapy-induced vomiting of colorectal cancer.Methods: this study was conducted retrospectively. 64 patients with colorectal cancer in our hospital from November 2019 to March 2021 were divided into control group (32 cases, routine chemotherapy) and observation group (32 cases, plus megestrol);The incidence and specific degree of vomiting, body mass index and health status before and after treatment were observed.Results: the incidence of vomiting was only 6.2% in the observation group and 25.0% in the control group (P < 0.05).In the observation group treated with megestrol acetate, the body mass index tended to be normal and the health status was better. The data of the two groups were compared (P < 0.05).Conclusion: megestrol is effective in the treatment of chemotherapy-induced vomiting of colorectal cancer, which can reduce the incidence of vomiting and improve the prognosis of patients.展开更多
Objective:To analyze the clinical efficacy of megestrol acetate dispersible tablets in the adjuvant treatment of acute leukemia.Methods:80 patients with acute leukemia admitted from December 2021 to December 2022 were...Objective:To analyze the clinical efficacy of megestrol acetate dispersible tablets in the adjuvant treatment of acute leukemia.Methods:80 patients with acute leukemia admitted from December 2021 to December 2022 were randomly divided into two groups.The control group underwent chemotherapy,and the observation group took megestrol acetate dispersible tablets and underwent chemotherapy.The effect of the treatments were evaluated by analyzing the albumin(Alb)and prealbumin(Palb)indicators,and the adverse reactions were observed.Results:There was no significant difference in Alb and Palb indexes between the two groups before treatment(P>0.05).After treatment,Alb and Palb indexes in the observation group were greater than those in the control group(P<0.05).The incidence of adverse reactions in the control group was 20.00%,which was significantly higher than the observation group(5.00%),with P<0.05.Conclusion:The combination of megestrol acetate dispersible tablets and chemotherapy is more effective in treating patients with acute leukemia,and the Alb and Palb indexes can be optimized.Besides,there are fewer adverse reactions,which means that the treatment is relatively safe.展开更多
Objective: To find effective therapeutic approach for treating true idiopathic precocious puberty suitable to our national condition and different from gonadotrophin releasing hormone analogue. Methods: One hundred an...Objective: To find effective therapeutic approach for treating true idiopathic precocious puberty suitable to our national condition and different from gonadotrophin releasing hormone analogue. Methods: One hundred and six girls with idiopathic precocious puberty were divided into 3 groups. The 51 girls in the TCMWM group were treated with Chinese herbal medicine combined with megestrol acetate (MA), 35 girls in the MA group treated with megestrol acetate alone, and 20 girls were taken as control group and given no treatment at all. Luteinizing hormone releasing hormone (LHRH) stimulating test were performed before and after treatment, and the size of the uterus and ovary, linear growth rate, X-ray bone age measurement and final height prediction were also observed simultaneously. Results: After treated with TCM-WM for 2.7 years in average,the luteinizing hormone (LH) peak value of LHRH stimulating test was reduced from 48. 5 ± 5. 2 IU/L to 12.2 ± 1. 3 IU/L, size of uterus and ovary decreased, secondary sexual characteristics regressed, the bone age difference/chronological age difference value (ΔBA/ΔCA) reduced from 1. 35 ± 0. 09 to 0. 65 ± 0. 05 and predictive final height increased from 153. 3 ± 0. 5 cm to 158. 5 ± 0. 6 cm. Conclusion: TCM-WM therapy could not only modulate the function of hypothalamic-pituitary-ovarian axis and the development of internal genitalia, but also could decelerate skeletal growth, delay skeletal maturation, and thereby prevent premature epiphyseal fusion and increase the final height of patients.展开更多
Objective: To observe the therape utic effect of arsenious acid combined with Tα-1 thymus peptide and megestro l acetate on advanced non-small cell lung cancer.Methods: Nintey-two patients were divided randomly into...Objective: To observe the therape utic effect of arsenious acid combined with Tα-1 thymus peptide and megestro l acetate on advanced non-small cell lung cancer.Methods: Nintey-two patients were divided randomly into the tr eated group( n =45) and the control group( n =47). The treated group were tr eated with arsenious acid combined with Tα-1 thymus peptide and megestrol ac etate, and the control group were treated with chemotherapy in the NP protocol .Results: (1) Therapeutic effect :In the 36 patients of the treated group, 2 were evaluated as CR, 8 as PR, 9 as MR, 8 as SD and 9 as PD, the CR+PR rate being 27.7% (10/36), while in the 40 patients of the control group, the co rresponding numbers were 3, 10, 11, 9, 7 and 32.5% (13/40). Comparison between t he CR+PR rate between the two groups showed insignificant difference ( P >0.05 ). (2)Clinical benefit rate: The positive rate of Karnofsky scores in the treate d group and the control group was 44.4% and 20.0% respectively; and the positive rate of body weight in the two groups was 33.3% and 12.5% respectively, the dif ference between the two groups was significant ( all P <0.05). (3)Changes of T- cell subsets and NK cell activity: CD4 and CD4/CD8 ratio after treatment i n the treated group increased significantly ( P <0.05), while in the control group, CD3, CD4, CD4/CD8 ratio and NK cell activity all lowered significantly ( P <0.01). Comparison between the two groups after treatment showed significa nt difference in CD4, CD4/CD8 ratio and NK cell activity, with those in the trea ted group all higher than those in the control group ( P <0.01). (4)Adeverse -reaction: No serious adverse reaction was found in both two groups. (5)Media n survival period:The treated group was 30 weeks and that in the control group w as 28.5 weeks, and the difference between the two groups was insignificant ( P >0.05).Conclusion: Arsenious acid combined with Tα-1 thymus peptide and megestrol acetate was a relatively effective scheme with low toxicity in tre ating advanced NSCLC.展开更多
文摘Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinoma(G1 EAC)and the recurrence rate after treatment.Methods Sixty patients(aged 20-42 years)with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups(n=30)to receive oral MA treatment at the daily dose of 160 mg(control)or MA plus oral metformin(850 mg,twice a day)for at least 6 months.The treatment could extend to 12 months until a complete response(CR)was achieved,and follow-up hysteroscopy and curettage were performed every 3 months.For all the patients who achieved CR,endometrial expressions of IGFBP-rP1,p-Akt and p-AMPK were detected immunohistochemically.Results A total of 58 patients completed the treatment.After 9 months of treatment,23(76.7%)patients in the combined treatment group and 20(71.4%)in the control group achieved CR;two patients in the control group achieved CR after converting to the combined treatment.The recurrence rate did not differ significantly between the control group and combined treatment group(30.0%vs 22.7%,P>0.05).Ten(35.7%)patients in the control group experienced significant weight gain of 5.7±6.1 kg,while none of the patients receiving the combined treatment exhibited significant body weight changes.Compared with the control group,the patients receiving the combined treatment showed enhanced endometrial expressions of IGFBP-rP1 and p-AMPK with lowered p-Akt expression.Conclusion Metformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC,and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.
基金Supported by Huguo Temple Hospital of Traditional Chinese Medicine Affiliated to Beijing University of Traditional Chinese Medicine:2017-3
文摘Objective:To observe the clinical effect difference between abdominal acupuncture combined with megestrol acetate and megestrol acetate for advanced cancer-related anorexia.Methods:A total of 60 patients with advanced cancer-related anorexia were randomly divided into an abdominal acupuncture combined with oral megestrol acetate treatment group(group A)and oral megestrol acetate treatment group(group B),with 30 cases in each group.Both groups were given nutritional assessment,nutritional supplementation,improvement of constipation,correction of electrolyte disturbance and other general treatments.In addition,group B was given another 160 mg megestrol acetate dispersible tablet once a day.Group A was treated with abdominal acupuncture on the basis of group B treatment,5 times a week,and both the groups were treated for 2 weeks.The appetite visual analog scale(VAS),Karnofsky(KPS)score,and body weight of the two groups were observed before and after treatment,and the clinical efficacy was evaluated.Results:After treatment,the appetite VAS in the both groups were lower than those before treatment,the Karnofsky(KPS)scores were higher than those before treatment,and the differences were statistically significant(both P<0.05).The differences of appetite VAS and KPS score before and after treatment in group A were higher than those of group B,and the differences were statistically significant(both P<0.05).After treatment,the body weights of the two groups were higher than those before treatment,and the difference of group A before and after treatment was higher than that of group B,but the difference was not statistically significant(P>0.05).The effective rate of group A was 76.7%and that of group B was 50%,the difference was statistically significant(P<0.05).Conclusion:Abdominal acupuncture combined with oral megestrol acetate and oral megestrol acetate both can effectively improve the appetite and functional status of patients with advanced cancer-related anorexia.Abdominal acupuncture can improve the curative effect,which is better than that of western medication alone,providing a new idea for the treatment of advanced cancer-related anorexia in the future.
基金supported by the Foundation of the Zhejiang Xianju Pharmaceutical Co.Ltd(China)
文摘A rapid and highly selective liquid chromatography-tandem mass spectrometric （LC-MS/MS） method for the determination of megestrol in human plasma was described using medry- sone as internal standard （IS）. Blood samples were collected from 20 healthy volunteers after oral ad- ministration of 160 mg megestrol acetate dispersible tablets. The analytes were extracted by liq- uid-liquid extraction procedure and separated on a hanbon lichrospher column with the mobile phase of methanol and water containing 0.1% formic acid and 20 mmol/L ammonium acetate （5：1, v/v）. Positive ion electrospray ionization with multiple reaction-monitoring mode （MRM） was employed by monitor- ing the transitions m/z 385.5-325.4 and m/z 387.5-327.4 for megestrol and medrysone, respectively. Under the isocratic separation conditions, the chromatographic rim time was approximately 2.54 min for megestrol and 2.59 min for medrysone. The calibration curve range was from 0.5 to 200.0 ng/mL. The inter-batch and intra-batch precision and accuracy were less than 5.2% relative standard deviation （RSD） and 6.4% relative error （RE）. The proposed method was successfully applied in the bioequivalence study of megestrol acetate dispersible tablets.
文摘Objective: to study the effect and value of megestrol in the clinical treatment of chemotherapy-induced vomiting of colorectal cancer.Methods: this study was conducted retrospectively. 64 patients with colorectal cancer in our hospital from November 2019 to March 2021 were divided into control group (32 cases, routine chemotherapy) and observation group (32 cases, plus megestrol);The incidence and specific degree of vomiting, body mass index and health status before and after treatment were observed.Results: the incidence of vomiting was only 6.2% in the observation group and 25.0% in the control group (P < 0.05).In the observation group treated with megestrol acetate, the body mass index tended to be normal and the health status was better. The data of the two groups were compared (P < 0.05).Conclusion: megestrol is effective in the treatment of chemotherapy-induced vomiting of colorectal cancer, which can reduce the incidence of vomiting and improve the prognosis of patients.
文摘Objective:To analyze the clinical efficacy of megestrol acetate dispersible tablets in the adjuvant treatment of acute leukemia.Methods:80 patients with acute leukemia admitted from December 2021 to December 2022 were randomly divided into two groups.The control group underwent chemotherapy,and the observation group took megestrol acetate dispersible tablets and underwent chemotherapy.The effect of the treatments were evaluated by analyzing the albumin(Alb)and prealbumin(Palb)indicators,and the adverse reactions were observed.Results:There was no significant difference in Alb and Palb indexes between the two groups before treatment(P>0.05).After treatment,Alb and Palb indexes in the observation group were greater than those in the control group(P<0.05).The incidence of adverse reactions in the control group was 20.00%,which was significantly higher than the observation group(5.00%),with P<0.05.Conclusion:The combination of megestrol acetate dispersible tablets and chemotherapy is more effective in treating patients with acute leukemia,and the Alb and Palb indexes can be optimized.Besides,there are fewer adverse reactions,which means that the treatment is relatively safe.
文摘Objective: To find effective therapeutic approach for treating true idiopathic precocious puberty suitable to our national condition and different from gonadotrophin releasing hormone analogue. Methods: One hundred and six girls with idiopathic precocious puberty were divided into 3 groups. The 51 girls in the TCMWM group were treated with Chinese herbal medicine combined with megestrol acetate (MA), 35 girls in the MA group treated with megestrol acetate alone, and 20 girls were taken as control group and given no treatment at all. Luteinizing hormone releasing hormone (LHRH) stimulating test were performed before and after treatment, and the size of the uterus and ovary, linear growth rate, X-ray bone age measurement and final height prediction were also observed simultaneously. Results: After treated with TCM-WM for 2.7 years in average,the luteinizing hormone (LH) peak value of LHRH stimulating test was reduced from 48. 5 ± 5. 2 IU/L to 12.2 ± 1. 3 IU/L, size of uterus and ovary decreased, secondary sexual characteristics regressed, the bone age difference/chronological age difference value (ΔBA/ΔCA) reduced from 1. 35 ± 0. 09 to 0. 65 ± 0. 05 and predictive final height increased from 153. 3 ± 0. 5 cm to 158. 5 ± 0. 6 cm. Conclusion: TCM-WM therapy could not only modulate the function of hypothalamic-pituitary-ovarian axis and the development of internal genitalia, but also could decelerate skeletal growth, delay skeletal maturation, and thereby prevent premature epiphyseal fusion and increase the final height of patients.
文摘Objective: To observe the therape utic effect of arsenious acid combined with Tα-1 thymus peptide and megestro l acetate on advanced non-small cell lung cancer.Methods: Nintey-two patients were divided randomly into the tr eated group( n =45) and the control group( n =47). The treated group were tr eated with arsenious acid combined with Tα-1 thymus peptide and megestrol ac etate, and the control group were treated with chemotherapy in the NP protocol .Results: (1) Therapeutic effect :In the 36 patients of the treated group, 2 were evaluated as CR, 8 as PR, 9 as MR, 8 as SD and 9 as PD, the CR+PR rate being 27.7% (10/36), while in the 40 patients of the control group, the co rresponding numbers were 3, 10, 11, 9, 7 and 32.5% (13/40). Comparison between t he CR+PR rate between the two groups showed insignificant difference ( P >0.05 ). (2)Clinical benefit rate: The positive rate of Karnofsky scores in the treate d group and the control group was 44.4% and 20.0% respectively; and the positive rate of body weight in the two groups was 33.3% and 12.5% respectively, the dif ference between the two groups was significant ( all P <0.05). (3)Changes of T- cell subsets and NK cell activity: CD4 and CD4/CD8 ratio after treatment i n the treated group increased significantly ( P <0.05), while in the control group, CD3, CD4, CD4/CD8 ratio and NK cell activity all lowered significantly ( P <0.01). Comparison between the two groups after treatment showed significa nt difference in CD4, CD4/CD8 ratio and NK cell activity, with those in the trea ted group all higher than those in the control group ( P <0.01). (4)Adeverse -reaction: No serious adverse reaction was found in both two groups. (5)Media n survival period:The treated group was 30 weeks and that in the control group w as 28.5 weeks, and the difference between the two groups was insignificant ( P >0.05).Conclusion: Arsenious acid combined with Tα-1 thymus peptide and megestrol acetate was a relatively effective scheme with low toxicity in tre ating advanced NSCLC.
